Agen wins D-dimer patent case against Innogenetics
This article was originally published in Clinica
Australian biotechnology company Agen claims that a European patent decision in its favour has opened the door to further development of its D-dimer blood clotting marker. The European patent court in Munich found for Agen and against Innogenetics, without recourse for further appeal from the losing company, strengthening Agen's patent position worldwide.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.